# OKYO Pharma Limited (OKYO)

Source: https://www.quantisnow.com/company/OKYO
Generated: 2026-11-22T22:09:05.245Z

- Ticker: OKYO
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2022
- SEC CIK: 0001849296
- Website: https://www.okyopharma.com

## About

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. It is developing OK-101 for the treatment of dry eye disease; and OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. The company is also developing chemerin and chemerin analogues to treat the cytokine release syndrome associated with COVID-19 infections and other conditions, such as acute respiratory distress syndrome. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

## Latest OKYO news and filings

- 2026-11-20 21:05 UTC [SEC Schedule 13G] [SEC Form SCHEDULE 13G filed by OKYO Pharma Limited](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-okyo-pharma-limited-6802097)
- 2026-11-12 12:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by OKYO Pharma Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-okyo-pharma-limited-6786043)
- 2026-11-12 12:00 UTC [Conference Announcement] [OKYO Pharma to Participate in 2026 Jefferies Global Healthcare Conference in London](https://www.quantisnow.com/insight/okyo-pharma-to-participate-in-2026-jefferies-global-healthcare-conference-6785971)
- 2026-11-05 12:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by OKYO Pharma Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-okyo-pharma-limited-6774484)
- 2026-11-05 12:00 UTC [Conference Announcement] [OKYO Pharma to Present at the Stifel 2026 Healthcare Conference](https://www.quantisnow.com/insight/okyo-pharma-to-present-at-the-stifel-2026-healthcare-conference-6774392)
- 2026-10-06 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by OKYO Pharma Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-okyo-pharma-limited-6738064)
- 2026-10-06 11:00 UTC [OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain](https://www.quantisnow.com/insight/okyo-pharma-announces-first-patients-enrolled-in-phase-3-pivotal-6738031)
- 2026-09-29 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by OKYO Pharma Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-okyo-pharma-limited-6728324)
- 2026-09-29 11:00 UTC [OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences](https://www.quantisnow.com/insight/okyo-pharma-presents-and-participates-at-upcoming-ophthalmic-scientific-conferences-6728314)
- 2026-09-09 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by OKYO Pharma Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-okyo-pharma-limited-6709183)
- 2026-09-09 11:00 UTC [Conference Announcement] [OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026](https://www.quantisnow.com/insight/okyo-pharma-to-present-at-ophthalmology-futures-european-forum-and-6709172)
- 2026-09-08 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by OKYO Pharma Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-okyo-pharma-limited-6707379)
- 2026-09-08 11:00 UTC [Conference Announcement] [OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference](https://www.quantisnow.com/insight/okyo-pharma-to-participate-in-a-fireside-chat-at-the-6707345)
- 2026-08-07 20:30 UTC [Amendment: SEC Form 20-F/A filed by OKYO Pharma Limited](https://www.quantisnow.com/insight/amendment-sec-form-20-fa-filed-by-okyo-pharma-limited-6671818)
- 2026-08-07 20:15 UTC [Insider Buy] [Amendment: CHIEF DEVELOPMENT OFFICER Jacob Gary S bought $4,900 worth of shares (3,500 units at $1.40), increasing direct ownership by 3% to 112,420 units (SEC Form 4)](https://www.quantisnow.com/insight/amendment-chief-development-officer-jacob-gary-s-bought-4900-worth-6671648)
- 2026-08-07 20:15 UTC [Insider Buy] [Amendment: CHIEF EXECUTIVE OFFICER Dempsey Robert John bought $23,085 worth of shares (15,000 units at $1.54) (SEC Form 4)](https://www.quantisnow.com/insight/amendment-chief-executive-officer-dempsey-robert-john-bought-23085-worth-6671647)
- 2026-08-07 20:15 UTC [Insider Buy] [Amendment: Director Brancaccio John P bought $7,385 worth of shares (5,000 units at $1.48), increasing direct ownership by 17% to 35,201 units (SEC Form 4)](https://www.quantisnow.com/insight/amendment-director-brancaccio-john-p-bought-7385-worth-of-shares-6671644)
- 2026-08-07 20:15 UTC [Insider Buy] [Amendment: Chief Scientific Officer Patil Rajkumar V. bought $5,011 worth of shares (3,363 units at $1.49), increasing direct ownership by 20% to 20,030 units (SEC Form 4)](https://www.quantisnow.com/insight/amendment-chief-scientific-officer-patil-rajkumar-v-bought-5011-worth-6671643)
- 2026-08-07 20:15 UTC [Insider Buy] [Amendment: Director Cerrone Gabriele M bought $35,000 worth of shares (25,000 units at $1.40) (SEC Form 4)](https://www.quantisnow.com/insight/amendment-director-cerrone-gabriele-m-bought-35000-worth-of-shares-6671642)
- 2026-08-07 20:15 UTC [Insider Buy] [Amendment: Director Cerrone Gabriele M bought $32,625 worth of shares (22,500 units at $1.45) (SEC Form 4)](https://www.quantisnow.com/insight/amendment-director-cerrone-gabriele-m-bought-32625-worth-of-shares-6671640)
- 2026-08-07 20:15 UTC [Insider Buy] [Amendment: CHIEF MEDICAL OFFICER Mantelli Flavio bought $28,000 worth of shares (20,000 units at $1.40) (SEC Form 4)](https://www.quantisnow.com/insight/amendment-chief-medical-officer-mantelli-flavio-bought-28000-worth-of-6671637)
- 2026-07-29 20:45 UTC [SEC Form 4] [Chief Scientific Officer Patil Rajkumar V. was granted 3,363 shares, increasing direct ownership by 20% to 20,030 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-patil-rajkumar-v-was-granted-3363-shares-6654156)
- 2026-07-29 20:30 UTC [SEC Form 3] [New insider Patil Rajkumar V. claimed ownership of 16,667 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-patil-rajkumar-v-claimed-ownership-of-16667-shares-6654051)
- 2026-07-28 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by OKYO Pharma Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-okyo-pharma-limited-6650548)
- 2026-07-28 11:00 UTC [OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer](https://www.quantisnow.com/insight/okyo-pharma-announces-purchase-of-shares-by-chief-scientific-officer-6650518)
- 2026-07-27 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by OKYO Pharma Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-okyo-pharma-limited-6648918)
- 2026-07-27 11:00 UTC [Conference Announcement] [OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026](https://www.quantisnow.com/insight/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026-6648893)
- 2026-07-23 20:20 UTC [SEC Form 4] [CHIEF EXECUTIVE OFFICER Dempsey Robert John was granted 15,000 shares (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-dempsey-robert-john-was-granted-15000-shares-6647207)
- 2026-07-23 20:15 UTC [SEC Form 4] [Director Brancaccio John P was granted 5,000 shares, increasing direct ownership by 17% to 35,201 units (SEC Form 4)](https://www.quantisnow.com/insight/director-brancaccio-john-p-was-granted-5000-shares-increasing-direct-6647161)
- 2026-07-23 20:15 UTC [SEC Form 4] [Director Cerrone Gabriele M was granted 22,500 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-cerrone-gabriele-m-was-granted-22500-shares-sec-form-6647156)
- 2026-07-23 20:15 UTC [SEC Form 4] [CHIEF DEVELOPMENT OFFICER Jacob Gary S was granted 3,500 shares, increasing direct ownership by 3% to 112,420 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-development-officer-jacob-gary-s-was-granted-3500-shares-6647155)
- 2026-07-23 16:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by OKYO Pharma Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-okyo-pharma-limited-6646713)
- 2026-07-23 16:00 UTC [OKYO Pharma Announces Purchase of Shares by Director](https://www.quantisnow.com/insight/okyo-pharma-announces-purchase-of-shares-by-director-6646708)
- 2026-07-23 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by OKYO Pharma Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-okyo-pharma-limited-6646133)
- 2026-07-23 11:00 UTC [OKYO Pharma Announces Purchase of Shares by Chief Executive Officer](https://www.quantisnow.com/insight/okyo-pharma-announces-purchase-of-shares-by-chief-executive-officer-6646102)
- 2026-07-22 20:15 UTC [SEC Form 4] [CHIEF MEDICAL OFFICER Mantelli Flavio was granted 20,000 shares (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-mantelli-flavio-was-granted-20000-shares-sec-6645375)
- 2026-07-22 16:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by OKYO Pharma Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-okyo-pharma-limited-6644966)
- 2026-07-22 14:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by OKYO Pharma Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-okyo-pharma-limited-6644916)
- 2026-07-22 14:00 UTC [OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director](https://www.quantisnow.com/insight/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-6644909)
- 2026-07-22 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by OKYO Pharma Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-okyo-pharma-limited-6644544)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/OKYO
- Earnings history: https://www.quantisnow.com/earnings/OKYO
- Dividend history: https://www.quantisnow.com/dividends/OKYO
- Insider transactions: https://www.quantisnow.com/insiders/OKYO
- Options chain: https://www.quantisnow.com/options/OKYO
- SEC 8-K filings only: https://www.quantisnow.com/company/OKYO/8-k
- RSS and alerts for OKYO: https://www.quantisnow.com/docs/rss-feeds.md
